Cue Biopharma (CUE) EBITDA Margin (2018 - 2025)
Cue Biopharma's (CUE) quarterly EBITDA Margin came in at 242.62% in Q4 2025, up 84516.0% year-on-year from N/an in Q4 2024, and up 170.01% quarter-over-quarter from 346.53% in Q3 2025.
Cue Biopharma (CUE) EBITDA Margin (2018 - 2025) Analysis & Trends
Cue Biopharma has disclosed EBITDA Margin across 8 years of filings, most recently posting 242.62% for Q4 2025.
- EBITDA Margin for Q4 2025 came in at 242.62%, up 84516.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 34.19% (up 40378.0% YoY), and the FY2025 annual result was 19.96%, up 41801.0% from the prior year.
- EBITDA Margin came in at 242.62% for Q4 2025 at Cue Biopharma, up from 346.53% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 242.62% in Q4 2025 to a low of 50800.0% in Q2 2022.
- The 5-year median for EBITDA Margin is 660.82% (2024), against an average of 4721.07%.
- Across the five-year window, EBITDA Margin sank 5042472 bps in 2022 and jumped 4984841 bps in 2023, its largest moves.
- Cue Biopharma's EBITDA Margin stood at 101.57% in 2021, then tumbled by 9416 bps to 9666.23% in 2022, then jumped by 92 bps to 737.73% in 2023, then climbed by 18 bps to 602.54% in 2024, then soared by 140 bps to 242.62% in 2025.
- The last three EBITDA Margin figures came in at 242.62% (Q4 2025), 346.53% (Q3 2025), and 287.14% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cue Biopharma | 581.16 Mn | 553.47 Mn | - | 242.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 242.62% |
| Sep 30, 2025 | -346.53% |
| Jun 30, 2025 | -287.14% |
| Mar 31, 2025 | -2,911.40% |
| Dec 31, 2024 | -602.54% |
| Sep 30, 2024 | -259.59% |
| Jun 30, 2024 | -382.66% |
| Mar 31, 2024 | -719.10% |
| Dec 31, 2023 | -737.73% |
| Sep 30, 2023 | -523.81% |
| Jun 30, 2023 | -951.59% |
| Mar 31, 2023 | -6,979.68% |
| Dec 31, 2022 | -9,666.23% |
| Sep 30, 2022 | -16,245.59% |
| Jun 30, 2022 | -50,800.00% |
| Mar 31, 2022 | -1,425.50% |
| Dec 31, 2021 | -101.57% |
| Sep 30, 2021 | -542.51% |
| Jun 30, 2021 | -375.28% |
| Mar 31, 2021 | -805.67% |